<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="05d92b25-043c-4264-8910-c717cd316d50"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BLISOVI 24 Fe safely and effectively. See Full Prescribing Information for BLISOVI 24 Fe. Blisovi <sup>TM</sup> 24 Fe [norethindrone acetate and ethinyl estradiol tablets USP, (1 mg/0.02 mg) and ferrous fumarate tablets, (75 mg)] for Oral Use Initial U.S. Approval: 1968</title>
   <effectiveTime value="20250508"/>
   <setId root="1183b048-16f3-47a4-a42f-22ba07b2bb52"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650582310" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-864" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e797cf30-d0aa-4545-9a4f-2da058673c2e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250508"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-864" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Blisovi 24 Fe
</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>norethindrone acetate and ethinyl estradiol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-864-73" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20191107"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="24" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Blisovi 24 Fe
</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Norethindrone Acetate and Ethinyl Estradiol</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.02" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="1" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="9S44LIC7OJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NORETHINDRONE ACETATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="T18F433X4S" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NORETHINDRONE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5C5403N26O" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACACIA</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091398" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20191107"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                                    <originalText>white to off white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>round; flat face beveled edge</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;N21</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="4" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Inert
</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> Inert </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELLULOSE, MICROCRYSTALLINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R5L488RY0Q" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERROUS FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE K30</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091398" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20191107"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN">
                                    <originalText>brown mottled</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>round; flat face beveled edge</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;M22</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091398" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20191107"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID580">
               <id root="1d595538-2c69-423f-9932-5cc81d8b9ea5"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</title>
               <text>
                  <paragraph ID="ID581">
                     <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20191107"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID583">
                           <content styleCode="bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See Full Prescribing Information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">●        Blisovi 24 Fe is contraindicated in women over 35 years old who smoke. (<linkHtml href="#ID607">4</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">●        Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (<linkHtml href="#ID607">4</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID788">
               <id root="9404f7a2-20a6-4a4d-8c6a-6b8cba33de3a"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20230223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID791">Warnings and Precautions, Malignant Neoplasms (<linkHtml href="#ID631">5.11</linkHtml>)                                                                                       04/2022</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID792">
               <id root="0737e260-7fd4-4664-b4c9-1e97af5a291c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID793">Blisovi<sup>™</sup> 24 Fe is indicated for use by women to prevent pregnancy <content styleCode="italics">[see CLINICAL STUDIES (<linkHtml href="#ID709">14</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>The efficacy of Blisovi 24 Fe in women with a body mass index (BMI) of &gt; 35 kg/m<sup>2</sup> has not been evaluated.</paragraph>
               </text>
               <effectiveTime value="20220628"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID795">Blisovi 24 Fe is a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by women to prevent pregnancy.  (1) The efficacy of Blisovi 24 Fe in women with a body mass index (BMI) of &gt;35 kg/m<sup>2</sup> has not been evaluated. (<linkHtml href="#ID792">1</linkHtml>, <linkHtml href="#ID679">8.8</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID588">
               <id root="24a34e43-1c83-4af1-9033-6f48311f83f2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID600" styleCode="Disc">
                           <item>  Take one tablet by mouth at the same time every day for 28 days (<linkHtml href="#ID590">2.1</linkHtml>)</item>
                           <item>  Take tablets in the order directed on the blister pack (<linkHtml href="#ID590">2.1</linkHtml>)</item>
                           <item>  Blisovi 24 Fe may be administered without regard to meals (<linkHtml href="#ID697">12.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID590">
                     <id root="ed1090cc-c3b8-4032-9fef-fe7234773819"/>
                     <title>2.1 How to Start Blisovi 24 Fe</title>
                     <text>
                        <paragraph ID="ID591">Blisovi 24 Fe is dispensed in a blister card <content styleCode="italics">[see HOW SUPPLIED/STORAGE AND HANDLING (<linkHtml href="#ID711">16</linkHtml>)]</content>. Blisovi 24 Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception must be used until after the first 7 consecutive days of administration.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID592">
                     <id root="c6d65e11-4d23-4899-9b8f-136f4fec5194"/>
                     <title>2.2 How to Take Blisovi 24 Fe</title>
                     <text>
                        <paragraph ID="ID807">
                           <content styleCode="bold">Table 1:          Instructions for Administration of Blisovi 24 Fe </content>
                        </paragraph>
                        <table ID="ID593" width="590" styleCode="Noautorules">
                           <col width="247"/>
                           <col width="343"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Rrule" align="left">
                                    <content styleCode="bold"> Starting COCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="left">
                                    <content styleCode="bold"> Day 1 Start:</content>
                                    <br/> ●    Take first <content styleCode="bold"> white</content>  active tablet without regard to meals on the first day of menses.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <content styleCode="bold"> Important:</content>
                                    <br/> Consider the possibility of ovulation and conception prior to initiation of this product.<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    Take subsequent active tablets once daily at the same time each day for a total of 24 days.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <content styleCode="bold"> Tablet Color:</content>
                                    <br/> ●    Blisovi 24 Fe active tablets are white (Day 1 to Day 24).<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    Take one <content styleCode="bold"> brown</content>  inactive tablet daily for 4 days and at the same time of day that active tablets were taken.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> ●    Blisovi 24 Fe inactive tablets are brown (Day 25 to Day 28).<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last inactive tablet).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left">
                                    <content styleCode="bold"> Sunday Start:</content>
                                    <br/> For each 28-day course, take in the following order:<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    Take the <content styleCode="bold"> white </content> active tablet without regard to meals on the first Sunday after the onset of menses. <content styleCode="bold"> Due to the potential risk of becoming pregnant, use additional non- hormonal contraception (such as condoms and spermicide) for the first 7 days of the patient's first cycle pack of Blisovi 24 Fe.</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    Take subsequent active tablets once daily at the same time each day for a total of 24 days.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    Take one <content styleCode="bold"> brown </content> tablet (ferrous fumarate) daily for the following 4 days and at the same time of day that active tablets were taken. A scheduled period should occur during the 4 days that the brown tablets are taken.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Switching to Blisovi 24 Fe from</content>
                                    <content styleCode="bold"> another oral contraceptive</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Start on the same day that a new pack of the previous oral contraceptive would have started.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> S</content>
                                    <content styleCode="bold"> w</content>
                                    <content styleCode="bold"> itching from another contraceptive method to Blisovi 24 Fe </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Start Blisovi 24 Fe:</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●    Transdermal patch</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    On the day when next application would have been scheduled.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●    Vaginal ring</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    On the day when next insertion would have been scheduled<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●    Injection</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    On the day when next injection would have been scheduled<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <content styleCode="bold"> ●    Intrauterine contraceptive</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ●    On the day of removal<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle pack.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●    Implant</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●    On the day of removal<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID594">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="underline">Starting Blisovi 24 Fe after Abortion or Miscarriage</content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">First-trimester:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID781" styleCode="Disc">
                           <item>After a first-trimester      abortion or miscarriage, Blisovi 24 Fe may be started immediately. An      additional method of contraception is not needed if Blisovi 24 Fe is      started immediately.</item>
                           <item>If Blisovi      24 Fe is not started within 5 days after termination of the pregnancy, the      patient must use additional non-hormonal contraception (such as condoms      and spermicide) for the first 7 days of her first 28-day course of Blisovi      24 Fe.</item>
                        </list>
                        <paragraph ID="ID782">
                           <content styleCode="bold">
                              <content styleCode="italics">Second-trimester:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID783" styleCode="Disc">
                           <item>Do not start until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start Blisovi 24 Fe following the instructions in Table 1 for Sunday start. Use additional non-hormonal contraception (such as condoms and spermicide) for the first 7 days of the patient's first 28-day course of Blisovi 24 Fe <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>) and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>).</content>
                           </item>
                        </list>
                        <paragraph ID="ID784">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="underline">Starting Blisovi 24 Fe after Childbirth</content>
                              </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID785" styleCode="Disc">
                           <item>Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Blisovi 24 Fe following the instructions in Table 1 for women not currently using hormonal contraception.</item>
                           <item>If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of Blisovi 24 Fe <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>), WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>), USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID667">8.1</linkHtml> and <linkHtml href="#ID669">8.2</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID595">
                     <id root="cae14698-9c62-40bc-908e-f064c7212ed2"/>
                     <title>2.3 Missed Tablets</title>
                     <text>
                        <table ID="ID596" width="590" styleCode="Noautorules">
                           <caption>  Table 2:       Instructions for Missed Blisovi 24 Fe Tablets </caption>
                           <col width="294"/>
                           <col width="296"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> ●    If one active tablet is missed in Weeks 1, 2 or 3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Take the tablet as soon as possible. Take the next pill at the regular time and continue taking one tablet a day until the pack is finished. Back-up contraception is not needed<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> ●    If two consecutive active tablets are missed in Week 1 or Week 2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Take the two missed tablets as soon as possible and the next two active tablets the next day. Continue taking one tablet a day until the pack is finished. <content styleCode="bold"> Additional non-hormonal contraception (such as condoms and spermicide) must be used as back-up if the patient has sex within 7 days after missing tablets</content> .<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> ●    If two consecutive active tablets are missed in Week 3 or Week 4 or three or more consecutive active tablets are missed at any time<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="underline">Day 1 Start</content> : Throw out the rest of the pack and start a new pack that same day.<br/>
                                    <content styleCode="underline">Sunday Start</content> : Continue taking one tablet a day until Sunday, then throw out the rest of the pack and start a new pack that same day.<br/>
                                    <content styleCode="bold"> Additional non-hormonal contraception (such as condoms and spermicide) must be used as back-up if the patient has sex within 7 days after missing 3 tablets.</content>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID597">
                     <id root="1f2fa22c-9f6d-4c3e-ae37-acac55978173"/>
                     <title>2.4 Advice in Case of Gastrointestinal Disturbances</title>
                     <text>
                        <paragraph ID="ID598">In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures must be taken. If vomiting or diarrhea occurs within 3 to 4 hours after taking a white tablet, handle this as a missed tablet <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID596">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20211218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID601">
               <id root="e12fa209-4e43-412f-80e0-b3cfde89d8e8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID602">Blisovi 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) is available in blister packs.</paragraph>
                  <paragraph>Each blister pack (28 tablets) contains in the following order:</paragraph>
                  <list listType="unordered" ID="ID603" styleCode="Disc">
                     <item>24      white to off-white, round, flat face beveled edged (active) tablets      debossed with "LU" on one side and "N21" on the other side and      each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.</item>
                     <item>4 brown      mottled, round, flat face beveled edge (non-hormonal placebo) tablets      debossed with "LU" on one side and "M22" on the other side and      each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do      not serve any therapeutic purpose.</item>
                  </list>
               </text>
               <effectiveTime value="20211218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID605">Blisovi 24 Fe consists of 28 tablets in the following order (<linkHtml href="#ID601">3</linkHtml>):</paragraph>
                        <list listType="unordered" ID="ID606" styleCode="Disc">
                           <item>24 white tablets (active), each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol</item>
                           <item>4 brown tablets (non-hormonal placebo), each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID607">
               <id root="be79a588-f9cc-494e-b93a-569c11c0333a"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID608">Blisovi 24 Fe is contraindicated in females who are known to have or develop the following conditions:</paragraph>
                  <list listType="unordered" ID="ID609" styleCode="Disc">
                     <item>A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<list listType="unordered" styleCode="Circle">
                           <item>Smoke, if over age 35 <content styleCode="italics">[see BOXED WARNING and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have deep vein thrombosis or pulmonary embolism, now or in the past <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have inherited or acquired hypercoagulopathies <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have cerebrovascular disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have coronary artery disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have uncontrolled hypertension <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID617">5.4</linkHtml>)]</content>
                           </item>
                           <item>Have diabetes mellitus with vascular disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID621">5.6</linkHtml>)]</content>
                           </item>
                           <item>Have headaches with focal neurological symptoms or have migraine headaches with aura <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID623">5.7</linkHtml>)]</content>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph ID="ID786">■    Women over age 35 with any migraine headaches <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID623">5.7</linkHtml>)]</content>
                  </paragraph>
                  <list listType="unordered" ID="ID787" styleCode="Disc">
                     <item>Liver tumors, benign or malignant, or liver disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID615">5.2</linkHtml>)]</content>
                     </item>
                     <item>Undiagnosed abnormal uterine bleeding <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID666">5.8</linkHtml>)]</content>
                     </item>
                     <item>Current diagnosis of, or history of, breast cancer, which may be hormone sensitive <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (5.11)]</content>
                     </item>
                     <item>Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID796">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID611" styleCode="Disc">
                           <item>A high risk of arterial or venous thrombotic diseases (<linkHtml href="#ID607">4</linkHtml>)</item>
                           <item>Liver tumors or liver disease (<linkHtml href="#ID607">4</linkHtml>)</item>
                           <item>Undiagnosed abnormal uterine bleeding (<linkHtml href="#ID607">4</linkHtml>)</item>
                           <item>Breast cancer (<linkHtml href="#ID607">4</linkHtml>)</item>
                           <item>Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (<linkHtml href="#ID607">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID612">
               <id root="b637fa9b-fcc8-4144-8ab8-f1b1f485fee3"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID642" styleCode="Disc">
                           <item>Thrombotic Disorders and Other Vascular Problems: Stop Blisovi 24 Fe if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. (<linkHtml href="#ID613">5.1</linkHtml>)</item>
                           <item>Liver disease: Discontinue Blisovi 24 Fe if jaundice occurs. (<linkHtml href="#ID615">5.2</linkHtml>)</item>
                           <item>High blood pressure: If used in women with well-controlled hypertension, monitor blood pressure and stop Blisovi 24 Fe if blood pressure rises significantly. (<linkHtml href="#ID617">5.4</linkHtml>)</item>
                           <item>Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Blisovi 24 Fe<content styleCode="bold">. </content> Consider an alternative contraceptive method for women with uncontrolled dyslipidemia. (<linkHtml href="#ID621">5.6</linkHtml>)</item>
                           <item>Headache: Evaluate significant change in headaches and discontinue Blisovi 24 Fe if indicated. (<linkHtml href="#ID623">5.7</linkHtml>)</item>
                           <item>Bleeding Irregularities and Amenorrhea: Evaluate irregular bleeding or amenorrhea. (<linkHtml href="#ID625">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID613">
                     <id root="102b8013-beca-4e18-b2e4-461989aaa80d"/>
                     <title>5.1 Thrombotic Disorders and Other Vascular Problems</title>
                     <text>
                        <list listType="unordered" ID="ID614" styleCode="Disc">
                           <item>Stop Blisovi 24 Fe if an      arterial thrombotic event or venous thromboembolic (VTE) event occurs.</item>
                           <item>Stop Blisovi 24 Fe if there is      unexplained loss of vision, proptosis, diplopia, papilledema, or retinal      vascular lesions. Evaluate for retinal vein thrombosis immediately <content styleCode="italics">[see      ADVERSE REACTIONS (<linkHtml href="#ID650">6.2</linkHtml>)].</content>
                           </item>
                           <item>If feasible, stop Blisovi 24 Fe      at least 4 weeks before and through 2 weeks after major surgery or other      surgeries known to have an elevated risk of VTE as well as during the      following prolonged immobilization.</item>
                           <item>Start Blisovi 24 Fe no earlier      than 4 weeks after delivery, in women who are not breastfeeding. The risk      of postpartum VTE decreases after the third postpartum week, whereas the      risk of ovulation increases after the third postpartum week.</item>
                           <item>The use of COCs increases the      risk of VTE. However, pregnancy increases the risk of VTE as much or more      than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases      per 10,000 woman-years. The risk of VTE is highest during the first year      of use of a COCs and when restarting oral contraception after a break of 4      weeks or longer. The risk of thromboembolic disease due to COCs gradually      disappears after COC use is discontinued.</item>
                           <item>Use of COCs also increases the      risk of arterial thromboses such as strokes and myocardial infarctions,      especially in women with other risk factors for these events. COCs have      been shown to increase both the relative and attributable risks of      cerebrovascular events (thrombotic and hemorrhagic strokes). This risk      increases with age, particularly in women over 35 years of age who smoke.</item>
                           <item>Use COCs      with caution in women with cardiovascular disease risk factors.</item>
                        </list>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID615">
                     <id root="2c35dddc-12aa-4b8e-8790-562882a2f87e"/>
                     <title>5.2 Liver Disease</title>
                     <text>
                        <paragraph ID="ID616">
                           <content styleCode="bold">
                              <content styleCode="italics">Impaired Liver Function</content>
                           </content>
                        </paragraph>
                        <paragraph>Do not use Blisovi 24 Fe in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)]. </content>Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Blisovi 24 Fe if jaundice develops.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Liver Tumors</content>
                           </content>
                        </paragraph>
                        <paragraph>Blisovi 24 Fe is contraindicated in women with benign and malignant liver tumors <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)]</content>. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.</paragraph>
                        <paragraph>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt;8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.</paragraph>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID796">
                     <id root="1c6e8273-4f26-4b5b-994e-973f34304190"/>
                     <title>5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment</title>
                     <text>
                        <paragraph ID="ID797">During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue Blisovi 24 Fe prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)]</content>. Blisovi 24 Fe can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID617">
                     <id root="9a378a94-6285-44ec-b801-6c5920140dd3"/>
                     <title>5.4 High Blood Pressure</title>
                     <text>
                        <paragraph ID="ID618">Blisovi 24 Fe is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)]</content>. For women with well-controlled hypertension, monitor blood pressure and stop Blisovi 24 Fe if blood pressure rises significantly.</paragraph>
                        <paragraph>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID619">
                     <id root="da56abc6-259c-417d-92b1-b796095889ea"/>
                     <title>5.5 Gallbladder Disease</title>
                     <text>
                        <paragraph ID="ID620">Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC related cholestasis.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID621">
                     <id root="6dcea5c6-54a3-4cc7-9d3a-e87811eabf0d"/>
                     <title>5.6 Carbohydrate and Lipid Metabolic Effects</title>
                     <text>
                        <paragraph ID="ID622">Carefully monitor prediabetic and diabetic women who are taking Blisovi 24 Fe. COCs may decrease glucose tolerance.</paragraph>
                        <paragraph>Consider alternative contraception for women with uncontrolled dyslipidemias. A small proportion of women will have adverse lipid changes while on COCs.</paragraph>
                        <paragraph>Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID623">
                     <id root="780a882e-3b11-4597-98ae-5fe26ceed644"/>
                     <title>5.7 Headache</title>
                     <text>
                        <paragraph ID="ID624">If a woman taking Blisovi 24 Fe develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Blisovi 24 Fe if indicated.</paragraph>
                        <paragraph>Consider discontinuation of Blisovi 24 Fe in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event).</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID625">
                     <id root="c45c67bd-6636-48d9-b900-938e5b861692"/>
                     <title>5.8 Bleeding Irregularities and Amenorrhea</title>
                     <text>
                        <paragraph ID="ID626">
                           <content styleCode="bold">
                              <content styleCode="italics">Unscheduled Bleeding and Spotting</content>
                           </content>
                        </paragraph>
                        <paragraph>Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.</paragraph>
                        <paragraph>In a clinical trial of Blisovi 24 Fe, the frequency and duration of unscheduled bleeding and/or spotting was assessed in 743 women (3,823 28-day cycles). A total of 10 subjects (1.3%) discontinued Blisovi 24 Fe, at least in part, due to bleeding or spotting. Based on data from the clinical trial, [24 to 38%] of women using Blisovi 24 Fe experienced unscheduled bleeding per cycle in the six months of the trial. The percent of women who experienced unscheduled bleeding tended to decrease over time.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Amenorrhea and Oligomenorrhea</content>
                           </content>
                        </paragraph>
                        <paragraph>Women who use Blisovi 24 Fe may experience absence of withdrawal bleeding, even if they are not pregnant. In the clinical trial with Blisovi 24 Fe, 31 to 41% of the women using Blisovi 24 Fe did not have a withdrawal menses in at least one of 6 cycles of use. </paragraph>
                        <paragraph>Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was preexistent.</paragraph>
                        <paragraph>If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID627">
                     <id root="2816d0d6-d52b-4038-98b3-30a4d1795795"/>
                     <title>5.9 COC Use Before or During Early Pregnancy</title>
                     <text>
                        <paragraph ID="ID628">Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue Blisovi 24 Fe use if pregnancy is confirmed.</paragraph>
                        <paragraph>Administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID667">8.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID629">
                     <id root="f02b6320-b175-4d20-821d-f69d1ef54e76"/>
                     <title>5.10 Depression</title>
                     <text>
                        <paragraph ID="ID630">Carefully observe women with a history of depression and discontinue Blisovi 24 Fe if depression recurs to a serious degree.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID631">
                     <id root="7fb88525-8d52-4735-a4a5-748cc623276f"/>
                     <title>
                        <content styleCode="xmChange">5.11 Malignant Neoplasms</content>
                     </title>
                     <text>
                        <paragraph ID="ID632">
                           <content styleCode="xmChange">
                              <content styleCode="italics">Breast Cancer</content>
                              <br/>
                              <br/>
Blisovi 24 Fe is contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally sensitive <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>)].</content>
                              <br/>
                              <br/>
Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (&lt;6 months since last use) and current users with longer duration of COC use <content styleCode="italics">[see POSTMARKETING EXPERIENCE (<linkHtml href="#ID650">6.2</linkHtml>)].</content>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph ID="ID811">
                           <content styleCode="italics">Cervical Cancer</content>
                        </paragraph>
                        <paragraph>Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors.</paragraph>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID633">
                     <id root="61da3932-e8ba-45eb-bd50-9d1caaf88bde"/>
                     <title>5.12 Effect on Binding Globulins</title>
                     <text>
                        <paragraph ID="ID634">The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID635">
                     <id root="c4207679-0072-4333-a9b3-5341abc6227a"/>
                     <title>5.13 Monitoring</title>
                     <text>
                        <paragraph ID="ID636">A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID637">
                     <id root="14069eb6-57e9-48a6-8152-33a4a57c8c90"/>
                     <title>5.14 Hereditary Angioedema</title>
                     <text>
                        <paragraph ID="ID638">In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID639">
                     <id root="d5f19b26-44af-4504-bf83-6bd0862cc519"/>
                     <title>5.15 Chloasma</title>
                     <text>
                        <paragraph ID="ID640">Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking Blisovi 24 Fe.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID643">
               <id root="c16e4be6-e9ad-42d6-874f-3aaf0a4e1236"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID644">The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" ID="ID645" styleCode="Disc">
                     <item>Serious      cardiovascular events and stroke <content styleCode="italics">[see BOXED WARNING and WARNINGS AND      PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                     </item>
                     <item>Vascular      events <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)]</content>
                     </item>
                     <item>Liver disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID615">5.2</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph ID="ID646">Adverse reactions commonly reported by COC users are:</paragraph>
                  <list listType="unordered" ID="ID647" styleCode="Disc">
                     <item>Irregular      uterine bleeding</item>
                     <item>Nausea</item>
                     <item>Breast      tenderness</item>
                     <item>Headache</item>
                  </list>
               </text>
               <effectiveTime value="20250508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID653" styleCode="Disc">
                           <item>The most common adverse reactions (≥ 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, mood changes, bacterial vaginitis, acne, and weight gain. (<linkHtml href="#ID648">6.1</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID654">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID648">
                     <id root="fbc0e893-5934-4305-82a8-54f3c99879c3"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="ID649">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of Blisovi 24 Fe was evaluated in 743 subjects who participated in an open-label, randomized, active-controlled, multicenter clinical trial of Blisovi 24 Fe for contraception. This trial examined healthy, non-pregnant volunteers aged 18 to 45 years, who were sexually active and had a body mass index of ≤ 35 kg/m<sup>2</sup>. Subjects were followed for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Common Adverse Reactions (≥ 2% of all subjects)</content>
                           </content>
                        </paragraph>
                        <paragraph>The most common adverse reactions reported by at least 2% of the 743 women using Blisovi 24 Fe were the following, in order of decreasing incidence: headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), mood changes (including mood swings (2.2%) and depression (1.1%), bacterial vaginitis (3.1%), acne (2.7%), and weight gain (2.0%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Adverse Reactions Leading to Study Discontinuation</content>
                           </content>
                        </paragraph>
                        <paragraph>Among the 743 women using Blisovi 24 Fe, 46 women (6.2%) withdrew because of an adverse event. Adverse events occurring in 3 or more subjects leading to discontinuation of treatment were, in decreasing order: abnormal bleeding (0.9%), nausea (0.8%), mood changes (0.8%), menstrual cramps (0.4%), increased blood pressure (0.4%), and irregular bleeding (0.4%).</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="ID650">
                     <id root="8995592d-3872-429b-811c-80b471ba44a5"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID808">Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1).</paragraph>
                        <paragraph>Three studies compared breast cancer risk between current or recent COC users (&lt;6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM1"/>
                        <paragraph ID="ID651">RR = relative risk; OR = odds ratio; HR = hazard ratio. "ever COC" are females with current or past COC use; "never COC use" are females that never used COCs.</paragraph>
                        <paragraph>The following adverse reactions have been identified during post approval use of Blisovi 24 Fe. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular</content>
                           </content>
                        </paragraph>
                        <paragraph>Chest pain, palpitations, tachycardia, angina pectoris, myocardial infarction.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Endocrine Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Hypothyroidism, hyperthyroidism.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Eye Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Blurred vision, visual impairment, transient blindness, corneal thinning, change in corneal curvature (steepening).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">GI Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Nausea, vomiting, abdominal pain, constipation, pancreatitis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatobiliary Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Cholelithiasis, cholecystitis, hepatic adenoma, hemangioma of liver.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Immune System Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Anaphylactic reactions, including urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Infections</content>
                           </content>
                        </paragraph>
                        <paragraph>Vaginal infection.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism and Nutrition Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Change in weight or appetite (increase or decrease). hypoglycemia, diabetes mellitus, anemia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Myalgia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Skin and Subcutaneous Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Alopecia, rash (generalized and allergic), pruritus, skin discoloration, night sweats, swelling face or lips, hirsutism, skin burning sensation, erythema multiforme, erythema nodosum, hemorrhagic eruption.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Nervous System Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Headache, dizziness, migraine, hyperesthesia, paraesthesia, hypoaesthesia, somnolence, loss of consciousness, sensory disturbance.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Psychiatric Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Mood swings, depression, insomnia, anxiety, suicidal ideation, panic attack, changes in libido, bipolar disorder, dissociation, homicidal ideation.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal and Urinary Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Pollakiuria, dysuria, cystitis-like syndrome.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Reproductive System and Breast Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Breast changes (tenderness, pain, enlargement, and secretion), premenstrual syndrome, ovarian cyst, pelvic pain, ovarian cyst ruptured, pelvic fluid collection.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Vascular Disorders</content>
                           </content>
                        </paragraph>
                        <paragraph>Hot flush, thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein), migraine, transient ischemic attack, ischemic stroke.</paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID655">
               <id root="92e099e5-eab3-4e40-9c89-e5f0adad7e7c"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID656">Consult the labeling of concurrently used drugs to obtain further information about interactions with oral contraceptives or the potential for enzyme alterations.</paragraph>
               </text>
               <effectiveTime value="20230223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID664" styleCode="Disc">
                           <item>Drugs or herbal products that induce certain enzymes (for example CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs. (<linkHtml href="#ID657">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID657">
                     <id root="124da455-6acd-4407-be47-83ecc8b4384e"/>
                     <title>7.1 Effects of Other Drugs on Combined Oral Contraceptives</title>
                     <text>
                        <paragraph ID="ID658">
                           <content styleCode="bold">
                              <content styleCode="italics">Substances Decreasing the Plasma Concentrations of COCs and Potentially Diminishing the Efficacy of COCs</content>
                           </content>
                        </paragraph>
                        <paragraph>Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of oral contraceptives including phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between COCs and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Substances Increasing the Plasma Concentrations of COCs</content>
                           </content>
                        </paragraph>
                        <paragraph>Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors</content>
                           </content>
                        </paragraph>
                        <paragraph>Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritnoavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]).</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID659">
                     <id root="0e1ebbcb-b7d3-44f3-9348-277c2346131c"/>
                     <title>7.2 Effects of Combined Oral Contraceptives on Other Drugs</title>
                     <text>
                        <paragraph ID="ID660">COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.</paragraph>
                        <paragraph>Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID633">5.12</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID798">
                     <id root="d8d7ccd3-9e4c-4fbd-a251-0ba140c272ef"/>
                     <title>7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation</title>
                     <text>
                        <paragraph ID="ID799">Co-administration of Blisovi 24 Fe with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID796">5.3</linkHtml>)]</content>. Co-administration of Blisovi 24 Fe and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations.</paragraph>
                     </text>
                     <effectiveTime value="20230223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID661">
                     <id root="f2180255-3252-4b97-9e01-528254ea06b9"/>
                     <title>7.4 Interactions with Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID662">The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID666">
               <id root="2f5794fd-9119-4abc-92dd-4a3775da4daa"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID682" styleCode="Disc">
                           <item>Lactation: Advise use of another contraceptive method. Blisovi 24 Fe can decrease milk production. (<linkHtml href="#ID669">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID667">
                     <id root="969792d2-4617-48ca-a5c2-c60ab1720794"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID668">Risk Summary</paragraph>
                        <paragraph>There is no use for contraception in pregnancy; therefore, Blisovi 24 Fe should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to CHCs before conception or during early pregnancy.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.</paragraph>
                        <paragraph>Data</paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Epidemiologic studies and meta-analyses have not found an increased risk of genital or  nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to CHCs before conception or during early pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20211218"/>
                  </section>
               </component>
               <component>
                  <section ID="ID669">
                     <id root="2466e101-a654-4211-b7e4-9e84a05454b2"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID670">Risk Summary</paragraph>
                        <paragraph>Contraceptive hormones and/or metabolites are present in human milk. CHCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breastfeeding <content styleCode="italics">[see Dosage and</content> <content styleCode="italics">Administration (<linkHtml href="#ID588">2.2</linkHtml>)]. </content>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Blisovi 24 Fe and any potential adverse effects on the breastfed child from Blisovi 24 Fe or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20211218"/>
                  </section>
               </component>
               <component>
                  <section ID="ID671">
                     <id root="932988da-ea57-48a6-a49a-e606977f7a45"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID672">Safety and efficacy of Blisovi 24 Fe have been established in women of reproductive age. Efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID673">
                     <id root="59b81ea5-3558-4f24-9cf4-5c9ecbfb3310"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID674">Blisovi 24 Fe has not been studied in postmenopausal women and is not indicated in this population.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID675">
                     <id root="693b0381-bd62-4dfd-b0fd-16819e168d69"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID676">The pharmacokinetics of Blisovi 24 Fe has not been studied in subjects with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID607">4</linkHtml>) and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID615">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID677">
                     <id root="87b6e538-518f-4bc2-9227-4e6e3fc1a523"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID678">The pharmacokinetics of Blisovi 24 Fe has not been studied in women with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID679">
                     <id root="51c53afa-0736-4f69-85b6-c26c67dc2d53"/>
                     <title>8.8 Body Mass Index</title>
                     <text>
                        <paragraph ID="ID680">The safety and efficacy of Blisovi 24 Fe in women with a body mass index (BMI) &gt; 35 kg/m<sup>2</sup> has not been evaluated <content styleCode="italics">[see CLINICAL STUDIES (<linkHtml href="#ID709">14</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID683">
               <id root="4eb47a29-fc2d-457a-85c8-23cfc7ceb367"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID684">There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</paragraph>
               </text>
               <effectiveTime value="20191107"/>
            </section>
         </component>
         <component>
            <section ID="ID685">
               <id root="a4976a45-95bb-4cdb-9a2f-9e57ca239f4b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID686">Blisovi 24 Fe is a combination oral contraceptive for oral administration consisting of active tablets containing norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, and placebo tablets containing ferrous fumarate, which serve no therapeutic purpose.</paragraph>
                  <list listType="unordered" ID="ID687" styleCode="Disc">
                     <item>Each active white tablet      contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Inactive      ingredients include      acacia, confectioner's sugar, corn starch, lactose monohydrate,      magnesium stearate and talc.</item>
                     <item>Each      placebo brown tablet contains 75 mg ferrous fumarate, magnesium stearate,      microcrystalline cellulose, povidone, sodium starch glycolate, and      sucrose. The ferrous fumarate tablets do not serve any therapeutic      purpose. Ferrous fumarate tablets are not USP for dissolution.</item>
                  </list>
                  <paragraph ID="ID688">The chemical name of ethinyl estradiol is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The empirical formula of ethinyl estradiol is C<sub>20</sub>H<sub>24</sub>O<sub>2 </sub>and the structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID690">The chemical name of norethindrone acetate is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate. The empirical formula of norethindrone acetate is C<sub>22</sub>H<sub>28</sub>O<sub>3</sub> and the structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID812">"FDA approved dissolution test specifications differ from USP"</paragraph>
               </text>
               <effectiveTime value="20250508"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>image-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>image-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID692">
               <id root="d3a0050e-aca3-45b9-9556-bb7353c4c014"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241205"/>
               <component>
                  <section ID="ID693">
                     <id root="3f5c2d79-1cf0-4704-a650-05b703445de9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID694">CHCs prevent pregnancy primarily by suppressing ovulation.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID695">
                     <id root="ce5be7ab-5285-4a5c-b138-0d4afdefb19c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID696">No specific pharmacodynamic studies were conducted with Blisovi 24 Fe.</paragraph>
                     </text>
                     <effectiveTime value="20191107"/>
                  </section>
               </component>
               <component>
                  <section ID="ID697">
                     <id root="edfe05f5-fb84-47ef-884c-ec15289705e2"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID698">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, because the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed from Blisovi 24 Fe tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 4 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol.</paragraph>
                        <paragraph>The plasma norethindrone and ethinyl estradiol pharmacokinetics following single- and multiple-dose administrations of Blisovi 24 Fe tablets in 17 healthy female volunteers are provided in Figures 2 and 3, and Table 3.</paragraph>
                        <paragraph>Following multiple-dose administration of Blisovi 24 Fe tablets, mean maximum concentrations of norethindrone and ethinyl estradiol were increased by 95% and 27%, respectively, as compared to single-dose administration. Mean norethindrone and ethinyl estradiol exposures (AUC values) were increased by 164% and 51% respectively, as compared to single-dose administration of Blisovi 24 Fe tablets.</paragraph>
                        <paragraph>Steady-state with respect to norethindrone was reached by Day 17 and steady-state with respect to ethinyl estradiol was reached by Day 13.</paragraph>
                        <paragraph>Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) to 144 nmol/L at steady-state.</paragraph>
                        <paragraph ID="ID699">
                           <content styleCode="bold">Figure 2. Mean Plasma Norethindrone Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Blisovi 24 Fe Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                        <paragraph ID="ID702">
                           <content styleCode="bold">Figure 3. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following Single- and Multiple-Dose Oral Administration of Blisovi 24 Fe Tablets to Healthy Female Volunteers Under Fasting Condition (n = 17)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM5"/>
                        <table ID="ID704" width="100%">
                           <caption>Table 3. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Blisovi 24 Fe Tablets to Healthy Female Volunteers Under Fasting Condition (n =17)</caption>
                           <col width="11%"/>
                           <col width="11%"/>
                           <col width="13%"/>
                           <col width="16%"/>
                           <col width="12%"/>
                           <col width="11%"/>
                           <col width="13%"/>
                           <col width="13%"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" colspan="1" styleCode=" Lrule Rrule Toprule">
                                    <content styleCode="bold">Regimen</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" colspan="1" styleCode=" Lrule Rrule Toprule">
                                    <content styleCode="bold">Analyte</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" colspan="6" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Arithmetic </content>Mean<footnote ID="ID704_1">The harmonic mean (0.693/mean apparent elimination rate constant) is reported for t<sub>½</sub>, and the median (range) is reported for t<sub>m</sub>
                                       <sub>a</sub>
                                       <sub>x</sub>.</footnote> <content styleCode="bold">(%</content>
                                    <content styleCode="bold">CV</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">by </content>
                                    <content styleCode="bold">Pharmacokinetic </content>
                                    <content styleCode="bold">Parameter</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule">
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule">
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">C<sub>m</sub>
                                       <sub>a</sub>
                                       <sub>x</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">pg</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">mL</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">t<sub>m</sub>
                                       <sub>a</sub>
                                       <sub>x</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">hr</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">AUC</content>
                                    <content styleCode="bold">
                                       <sub>(</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>0</sub>
                                       <sub> </sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>t</sub>
                                       <sub>o</sub>
                                       <sub> </sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>2</sub>
                                       <sub>4</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>)</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">pg</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">mL</content>
                                    <content styleCode="bold">●</content>
                                    <content styleCode="bold">h</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">C<sub>m</sub>
                                       <sub>i</sub>
                                       <sub>n</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">pg</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">mL</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">t<sub>1</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>/</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>2</sub>
                                    </content>
                                    <content styleCode="bold"/>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">hr</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">C<sub>a</sub>
                                       <sub>v</sub>
                                       <sub>g</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">pg</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">mL</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">NE<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8420 (31)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.0 (0.7 to 4.0)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">33390 (40)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule">Day 1<br/>(Single<br/>Dose)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>EE<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">64.5 (27)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3 (0.7 to 4.0)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">465.4 (26)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>SHBG<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">57.5 (37)<footnote ID="ID704_2">The SHBG concentration reported here is the pre-dose concentration.</footnote>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">NE<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16400 (26)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3 (0.7 to 4.0)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">88160 (30)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">880 (51)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3670 (30)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule">Day 24<br/>(Multiple<br/>Dose)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>EE<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">81.9 (24)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.7 (1.0 to 2.0)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">701.3 (28)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11.4 (43)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">29.2 (28)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>SHBG<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">144 (24)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">--<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID773">C<sub>max</sub> = Maximum plasma concentration </paragraph>
                        <paragraph>t<sub>max</sub> = Time of C<sub>max</sub>
                        </paragraph>
                        <paragraph>C<sub>min</sub> = minimum plasma concentration at steady-state</paragraph>
                        <paragraph>AUC<sub>(0 to 24) </sub>= Area under plasma concentration versus time curve from 0 to 24 hours</paragraph>
                        <paragraph>t<sub>½</sub> = Apparent first-order terminal elimination half-life</paragraph>
                        <paragraph>C<sub>avg</sub> = Average plasma concentration = AUC<sub>(0 to 24)/24</sub>
                        </paragraph>
                        <paragraph>% CV = Coefficient of Variation (%)</paragraph>
                        <paragraph>SHBG = Sex Hormone Binding Globulin (nmol/L)</paragraph>
                        <paragraph ID="ID705">
                           <content styleCode="bold">
                              <content styleCode="italics">Food Effect</content>
                           </content>
                        </paragraph>
                        <paragraph>A single-dose administration of Blisovi 24 Fe tablet with food decreased the maximum concentration of norethindrone by 11% and increased the extent of absorption by 27% and decreased the maximum concentration of ethinyl estradiol by 30% but not the extent of absorption.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (&gt;95%); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.</paragraph>
                        <paragraph>Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of Blisovi 24 Fe tablets are approximately 8 hours and 14 hours, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20241205"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>image-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>image-4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID706">
               <id root="62872ab6-796f-4c15-a6af-410da5283961"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250508"/>
               <component>
                  <section ID="ID707">
                     <id root="44265759-f4c9-4dd0-9503-8335abb5b333"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID708">
                           <content styleCode="italics">[See WARNINGS AND PRECAUTIONS (<linkHtml href="#ID615">5.2</linkHtml>, <linkHtml href="#ID631">5.11</linkHtml>)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID709">
               <id root="bb2266ff-45f7-48d3-97a5-5450c70bbf7d"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID710">In an active-controlled clinical trial, 743 women 18 to 45 years of age were studied to assess the efficacy of Blisovi 24 Fe, for up to six 28-day cycles. The racial demographic of women randomized to Blisovi 24 Fe was: 69.5% Caucasian, 15.5% African-American, 10.4% Hispanic, 2.3% Asian and 2.3% Native American/Other. Women with body mass index (BMI) greater than 35 mg/m<sup>2</sup> were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study randomized to Blisovi 24 Fe, 38.9% had not used hormonal contraception immediately prior to enrolling in this study.</paragraph>
                  <paragraph>A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies among women aged 18 to 45 years in 3,565 treatment cycles during which no back-up contraception was used. The Pearl Index for Blisovi 24 Fe was 1.82 (95% confidence interval 0.59 to 4.25).</paragraph>
               </text>
               <effectiveTime value="20191107"/>
            </section>
         </component>
         <component>
            <section ID="ID711">
               <id root="c91fd15b-6edd-4441-a8e1-607816b109c3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20211218"/>
               <component>
                  <section ID="ID712">
                     <id root="e0b35ac3-8967-467c-a59c-1ea31ce911df"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph ID="ID713">Blisovi 24 Fe is available in a blister pack (NDC 68180-864-71) containing 28 tablets packed in a pouch (NDC 68180-864-71). Such three pouches are packaged in a carton (NDC 68180-864-73).</paragraph>
                        <paragraph>Each blister pack (28 tablets) contains in the following order:</paragraph>
                        <list listType="unordered" ID="ID714" styleCode="Disc">
                           <item>24      white to off-white, round, flat face beveled edged (active) tablets      debossed with "LU" on one side and "N21" on the other side and      each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.</item>
                           <item>4 brown      mottled, round, flat face beveled edge (non-hormonal placebo) tablets      debossed with "LU" on one side and "M22" on the other side and      each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do      not serve any therapeutic purpose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211218"/>
                  </section>
               </component>
               <component>
                  <section ID="ID715">
                     <id root="2b527b2d-b10f-40f5-b378-8ce9970e0242"/>
                     <title>16.2 Storage Conditions</title>
                     <text>
                        <list listType="unordered" ID="ID716" styleCode="Disc">
                           <item>Store at 20° C to 25° C (68° F to 77° F); excursions permitted from 15 to 30° C (59 to 86° F) [see USP Controlled Room Temperature].</item>
                           <item>Protect from light. Keep this drug and all drugs out of the reach of children.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID717">
               <id root="56e6b25e-bfa2-4cda-b61b-130cbe01472c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID718">Counsel patients to read the FDA-approved Patient Labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>Counsel patients about the following information:</paragraph>
                  <list listType="unordered" ID="ID719" styleCode="Disc">
                     <item>Cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs <content styleCode="italics">[see BOXED WARNING].</content>
                     </item>
                     <item>Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID613">5.1</linkHtml>)].</content>
                     </item>
                     <item>Blisovi 24 Fe does not protect against HIV infection (AIDS) and other sexually transmitted diseases.</item>
                     <item>Blisovi 24 Fe is not to be used during pregnancy; if pregnancy occurs during use of Blisovi 24 Fe instruct the patient to stop further use <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID627">5.9</linkHtml>)].</content>
                     </item>
                     <item>Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID592">2.2</linkHtml>)].</content>
                     </item>
                     <item>Use a back-up or alternative method of contraception when enzyme inducers are used with Blisovi 24 Fe <content styleCode="italics">[see DRUG INTERACTIONS (<linkHtml href="#ID657">7.1</linkHtml>)].</content>
                     </item>
                     <item>COCs may reduce breast milk production; this is less likely to occur if breastfeeding is well established <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID670">8.2</linkHtml>)].</content>
                     </item>
                     <item>Women who start COCs postpartum, and who has not yet had a period, must use an additional method of contraception until she has taken a white tablet for 7 consecutive days <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID592">2.2</linkHtml>)].</content>
                     </item>
                     <item>Amenorrhea may occur. Consider pregnancy in the event of amenorrhea at the time of the first missed period. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID625">5.8</linkHtml>)].</content>
                     </item>
                  </list>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID720">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) - 454 775</paragraph>
                  <paragraph>INDIA</paragraph>
                  <paragraph>Revised: December 2024</paragraph>
               </text>
               <effectiveTime value="20241205"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID721">
               <id root="0fdb0968-4efe-4a84-9554-661e49eaba65"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID722">
                     <content styleCode="bold">PATIENT INFORMATION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Blisovi<sup>™</sup> 24 Fe (bli-SO-vee EFF-EE)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use Blisovi 24 Fe if you smoke cigarettes and are over 35 years old</content>. Smoking increases your risk of serious cardiovascular side effects from hormonal birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>Blisovi 24 Fe is a birth control pill (hormonal contraceptive) used by women to prevent pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How does Blisovi 24 Fe work for contraception?</content>
                  </paragraph>
                  <paragraph>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.</paragraph>
                  <paragraph>Based on the results from the clinical study, about 1 to 4 out of 100 women may get pregnant during the first year they use Blisovi 24 Fe.</paragraph>
                  <paragraph>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
                  <paragraph ID="ID724">
                     <content styleCode="bold">Who should not take Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take Blisovi 24 Fe if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID725" styleCode="Disc">
                     <item>smoke and are over 35 years of age</item>
                     <item>had blood clots in your arms, legs, lungs, or eyes</item>
                     <item>had a problem with your blood that makes it clot more than normal</item>
                     <item>have certain heart valve problems or irregular heart beat that increases your risk of having blood clots</item>
                     <item>had a stroke</item>
                     <item>had a heart attack</item>
                     <item>have high blood pressure that cannot be controlled by medicine</item>
                     <item>have diabetes with kidney, eye, nerve, or blood vessel damage</item>
                     <item>have certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or any migraine headaches if you are over 35 years of age</item>
                     <item>have liver problems, including liver tumors</item>
                     <item>have any unexplained vaginal bleeding</item>
                     <item>had breast cancer</item>
                     <item>take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme "alanine aminotransferase" (ALT) in the blood.</item>
                  </list>
                  <paragraph ID="ID726">
                     <content styleCode="bold">If any of these conditions happen while you are taking Blisovi 24 Fe, stop taking Blisovi 24 Fe right away and talk to your healthcare provider. Use non-hormonal contraception (such as condoms and spermicide) when you stop taking Blisovi 24 Fe.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before taking Blisovi 24 Fe? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID727" styleCode="Disc">
                     <item>are pregnant      or think you may be pregnant</item>
                     <item>are depressed      now or have been depressed in the past</item>
                     <item>had yellowing      of your skin or eyes (jaundice) caused by pregnancy (cholestasis of      pregnancy)</item>
                     <item>are      breastfeeding or plan to breastfeed. Blisovi 24 Fe may decrease the amount      of breast milk you make. A small amount of the hormones in Blisovi 24 Fe      may pass into your breast milk. Talk to your healthcare provider about the      best birth control method for you while breastfeeding.</item>
                  </list>
                  <paragraph ID="ID728">
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins and herbal supplements.</paragraph>
                  <paragraph>Blisovi 24 Fe may affect the way other medicines work, and other medicines may affect how well Blisovi 24 Fe works.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>Read the <content styleCode="bold">Instructions for Use</content> at the end of this Patient Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible serious side effects of Blisovi 24 Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID729" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Like pregnancy, Blisovi 24 Fe may cause serious side effects,      including blood clots in your lungs, heart attack, or a stroke that may      lead to death.</content> Some other examples of serious blood clots include      blood clots in the legs or eyes.</item>
                  </list>
                  <paragraph ID="ID730">Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious blood clots are more likely to happen when you:</paragraph>
                  <list listType="unordered" ID="ID731" styleCode="Disc">
                     <item>first start taking birth      control pills</item>
                     <item>restart      the same or different birth control pills after not using them for a month      or more</item>
                  </list>
                  <paragraph ID="ID732">
                     <content styleCode="bold">Call your healthcare provider or go to a hospital emergency room right away if you have:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID733" styleCode="Disc">
                     <item>leg pain that will not go away</item>
                     <item>sudden severe shortness of      breath</item>
                     <item>sudden change in vision or      blindness</item>
                     <item>chest pain</item>
                     <item>a sudden, severe headache unlike      your usual headaches</item>
                     <item>weakness or numbness in your      arm or leg</item>
                     <item>trouble      speaking</item>
                  </list>
                  <paragraph ID="ID734">
                     <content styleCode="bold">Other serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID735" styleCode="Disc">
                     <item>
                        <content styleCode="bold">liver problems, including:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>rare liver tumors</item>
                           <item>jaundice (cholestasis), especially if you previously had cholestasis of pregnancy. Call your healthcare provider if you have yellowing of your skin or eyes.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">high blood pressure</content> . You should see your healthcare provider for a yearly check of your blood pressure.</item>
                     <item>
                        <content styleCode="bold">gallbladder problems</content>
                     </item>
                     <item>
                        <content styleCode="bold">changes in the sugar and fat (cholesterol and triglycerides) levels in your blood</content>
                     </item>
                     <item>
                        <content styleCode="bold">new or worsening headaches including migraine headaches</content>
                     </item>
                     <item>
                        <content styleCode="bold">depression</content>
                     </item>
                     <item>
                        <content styleCode="bold">possible cancer in your breast and cervix</content>
                     </item>
                     <item>
                        <content styleCode="bold">swelling of your skin especially around your mouth, eyes, and in your throat (angioedema). </content> Call your healthcare provider if you have a swollen face, lips, mouth tongue or throat, which may lead to difficulty swallowing or breathing. Your chance of having angioedema is higher if you have a history of angioedema.</item>
                     <item>
                        <content styleCode="bold">dark patches of skin around your forehead, nose, cheeks and around your mouth, especially during pregnancy (chloasma).</content> Women who tend to get chloasma should avoid spending a long time in sunlight, tanning booths, and under sun lamps while taking Blisovi 24 Fe. Use sunscreen if you have to be in the sunlight.</item>
                  </list>
                  <paragraph ID="ID736">
                     <content styleCode="bold">What are the most common side effects of Blisovi 24 Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID737" styleCode="Disc">
                     <item>headache</item>
                     <item>vaginal infections</item>
                     <item>nausea</item>
                     <item>menstrual cramps</item>
                     <item>breast tenderness</item>
                     <item>mood changes</item>
                     <item>acne</item>
                     <item>weight gain</item>
                  </list>
                  <paragraph ID="ID738">These are not all the possible side effects of Blisovi 24 Fe. For more information, ask your healthcare provider or pharmacist.</paragraph>
                  <paragraph>You may report side effects to the FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What else should I know about taking Blisovi 24 Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID740" styleCode="Disc">
                     <item>If you are scheduled for any      lab tests, tell your healthcare provider you are taking Blisovi 24 Fe.      Certain blood tests may be affected by Blisovi 24 Fe.</item>
                     <item>Blisovi 24 Fe does not protect      against HIV infection (AIDS) and other sexually transmitted infections.</item>
                  </list>
                  <paragraph ID="ID741">
                     <content styleCode="bold">How should I store Blisovi 24 Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID742" styleCode="Disc">
                     <item>Store Blisovi      24 Fe at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Store away      from light.</item>
                     <item>Keep Blisovi 24 Fe and all medicines out of the reach of children.</item>
                  </list>
                  <paragraph ID="ID743">
                     <content styleCode="bold">General information about the safe and effective use of Blisovi 24 Fe</content>
                     <content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Blisovi 24 Fe for a condition for which it was not prescribed. Do not give Blisovi 24 Fe to other people.</paragraph>
                  <paragraph>This Patient Information summarizes the most important information about Blisovi 24 Fe. You can ask your pharmacist or healthcare provider for information about Blisovi 24 Fe that is written for health professionals.</paragraph>
                  <paragraph>For more information, call Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or visit our website at www.lupinpharmaceuticals.com.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do birth control pills cause cancer?</content> </paragraph>
                  <paragraph>It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use.</paragraph>
                  <paragraph>If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. </paragraph>
                  <paragraph>Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I want to become pregnant?</content>
                  </paragraph>
                  <paragraph>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I know about my period when taking Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>Your periods may be lighter and shorter than usual. Some women may miss a period. Irregular vaginal bleeding or spotting may happen while you are taking Blisovi 24 Fe, especially during the first few months of use. This usually is not a serious problem. It is important to continue taking your pills on a regular schedule to prevent a pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content>
                  </paragraph>
                  <paragraph>White pills: norethindrone acetate and ethinyl estradiol</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>
                  </paragraph>
                  <paragraph>Brown pills: ferrous fumarate</paragraph>
                  <paragraph ID="ID810">
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Blisovi™ 24 Fe (bli-SO-vee EFF-EE)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information about taking Blisovi 24 Fe </content>
                  </paragraph>
                  <list listType="unordered" ID="ID744" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day at      the same time. Take the pills in the order directed on your blister.</item>
                     <item>Do not skip your pills, even if      you do not have sex often. If you miss pills (including starting the pack      late), <content styleCode="bold">you could get pregnant</content> . The more pills you miss, the more      likely you are to get pregnant.</item>
                     <item>If you have trouble remembering      to take Blisovi 24 Fe, talk to your healthcare provider.</item>
                     <item>When you first start taking      Blisovi 24 Fe, spotting or light bleeding in between your periods may      occur. Contact your healthcare provider if this does not go away after a      few months.</item>
                     <item>You may feel sick to your      stomach (nauseous), especially during the first few months of taking      Blisovi 24 Fe. If you feel sick to your stomach, do not stop taking the      pill. The problem will usually go away. If your nausea does not go away,      call your healthcare provider.</item>
                     <item>Missing pills can also cause      spotting or light bleeding, even when you take the missed pills later. On      the days you take 2 pills to make up for missed pills (see <content styleCode="bold">What should      I do if I miss any Blisovi 24 Fe pills?</content> below), you could also feel a      little sick to your stomach.</item>
                     <item>It is not uncommon to miss a      period. However, if you miss a period and have not taken Blisovi 24 Fe      according to directions, or miss <content styleCode="bold">2</content> periods in a row, or feel like you      may be pregnant, call your healthcare provider. If you have a positive      pregnancy test, you should stop taking Blisovi 24 Fe.</item>
                     <item>If you have vomiting or      diarrhea within <content styleCode="bold">3 to 4</content> hours of taking a white active pill, take      another white pill from your extra blister. If you do not have an extra blister,      take the next white pill in your blister. Continue taking all your      remaining pills in order. Start the first pill of your next blister the      day after finishing your current blister. This will be 1 day earlier than      originally scheduled. Continue on your new schedule.</item>
                     <item>If you have vomiting or      diarrhea for more than 1 day, your birth control pills may not work as      well. Use an additional birth control method, like condoms and a      spermicide, until you check with your healthcare provider.</item>
                     <item>Stop      taking Blisovi 24 Fe at least <content styleCode="bold">4</content> weeks before you have major surgery      and do not restart after the surgery without asking your healthcare      provider. Be sure to use other forms of contraception (like condoms and      spermicide) during this time period.</item>
                  </list>
                  <paragraph ID="ID745">
                     <content styleCode="bold">Before you start taking Blisovi 24 Fe:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID746" styleCode="Disc">
                     <item>Decide what time of day you      want to take your pill. It is important to take it at the same time every      day and in the order as directed on your blister.</item>
                     <item>Have      backup contraception (condoms and spermicide) available and if possible,      an extra full pack of pills as needed.</item>
                  </list>
                  <paragraph ID="ID747">
                     <content styleCode="bold">When should I start taking Blisovi 24 Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you start taking Blisovi 24 Fe and you have not used a hormonal birth control method before:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID749" styleCode="Disc">
                     <item>There are 2 ways to start      taking your birth control pills. You can either start on a Sunday (Sunday      Start) or on the first day (Day 1) of your natural menstrual period (Day 1      Start). Your healthcare provider should tell you when to start taking your      birth control pill.</item>
                     <item>If you use      the Sunday Start, use non-hormonal back-up contraception such as condoms      and spermicide for the first <content styleCode="bold">7</content> days that you take Blisovi 24 Fe.      You do not need back-up contraception if you use the Day 1 Start.</item>
                  </list>
                  <paragraph ID="ID750">
                     <content styleCode="bold">If you start taking Blisovi 24 Fe and you are switching from another birth control pill:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID751" styleCode="Disc">
                     <item>Start your new Blisovi 24 Fe      pack on the same day that you would start the next pack of your previous      birth control method.</item>
                     <item>Do not      continue taking the pills from your previous birth control pack.</item>
                  </list>
                  <paragraph ID="ID752">
                     <content styleCode="bold">If you start taking Blisovi 24 Fe and previously used a vaginal ring or transdermal patch:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID753" styleCode="Disc">
                     <item>Start using Blisovi 24 Fe on the day you would have reapplied the      next ring or patch.</item>
                  </list>
                  <paragraph ID="ID754">
                     <content styleCode="bold">If you start taking Blisovi 24 Fe and you are switching from a progestin-only method such as an implant or injection:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID755" styleCode="Disc">
                     <item>Start      taking Blisovi 24 Fe on the day of removal of your implant or on the day      when you would have had your next injection.</item>
                  </list>
                  <paragraph ID="ID756">
                     <content styleCode="bold">If you start taking Blisovi 24 Fe and you are switching from an intrauterine device or system (IUD or IUS):</content>
                  </paragraph>
                  <list listType="unordered" ID="ID757" styleCode="Disc">
                     <item>Start taking Blisovi 24 Fe on      the day of removal of your IUD or IUS.</item>
                     <item>You do not      need back-up contraception if your IUD or IUS is removed on the first day      (Day 1) of your period. If your IUD or IUS is removed on any other day,      use non-hormonal back-up contraception such as condoms and spermicide for      the first <content styleCode="bold">7</content> days that you take Blisovi 24 Fe.</item>
                  </list>
                  <paragraph ID="ID758">
                     <content styleCode="bold">Keep a calendar to track your period:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If this is the first time</content> you are taking birth control pills, read, "<content styleCode="bold">When should I start taking Blisovi 24 Fe?</content>" above. Follow these instructions for either a <content styleCode="bold">Sunday Start</content> or a <content styleCode="bold">Day 1 Start</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sunday Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Sunday Start</content> if your healthcare provider told you to take your first pill on a Sunday.</paragraph>
                  <list listType="unordered" ID="ID759" styleCode="Disc">
                     <item>Take pill <content styleCode="bold">1</content> on the      Sunday <content styleCode="bold">after your period starts</content> .</item>
                     <item>If your period starts on a      Sunday, take pill "<content styleCode="bold">1</content> " that day and refer to Day 1 Start      instructions below.</item>
                     <item>Take <content styleCode="bold">1</content> pill every day in      the order on the blister at the same time each day for <content styleCode="bold">28</content> days.</item>
                     <item>After taking the last pill on <content styleCode="bold">Day      28</content> from the blister, start taking the first pill from a new pack, on      the same day of the week as the first pack (Sunday). Take the first pill      in the new pack whether or not you are having your period.</item>
                     <item>Use      non-hormonal back-up contraception such as condoms and spermicide for the      first <content styleCode="bold">7</content> days of the first cycle that you take Blisovi 24 Fe.</item>
                  </list>
                  <paragraph ID="ID760">
                     <content styleCode="bold">Day 1 Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Day 1 Start</content> if your doctor told you to take your first pill (Day 1) on the <content styleCode="bold">first day of your period.</content>
                  </paragraph>
                  <list listType="unordered" ID="ID761" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day in      the order of the blister, at the same time each day, for <content styleCode="bold">28</content> days.</item>
                     <item>After      taking the last pill on <content styleCode="bold">Day 28</content> from the blister, start taking the      first pill from a new pack, on the same day of the week as the first pack.      Take the first pill in the new pack whether or not you are having your      period.</item>
                  </list>
                  <paragraph ID="ID762">
                     <content styleCode="bold">Instructions for using your blister:</content>
                  </paragraph>
                  <paragraph>The Blisovi 24 Fe blister has 24 "active" white pills (with hormones) to be taken for <content styleCode="bold">24</content> days, followed by 4 "reminder" brown pills (without hormones) to be taken for the next <content styleCode="bold">4</content> days.</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph ID="ID764">Look for:</paragraph>
                  <list listType="unordered" ID="ID765" styleCode="Disc">
                     <item>Where on the      pack to start taking pills</item>
                     <item>In what order      to take the pills. Follow the arrows shown in <content styleCode="bold">Figure A</content> .</item>
                     <item>The week numbers as shown in <content styleCode="bold">Figure A</content> .</item>
                  </list>
                  <paragraph ID="ID766">
                     <content styleCode="bold">What if should I do if I miss any Blisovi 24 Fe white pills?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you miss 1 white pill in Weeks 1, 2, or 3, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID767" styleCode="Disc">
                     <item>Take it as soon as you      remember. Take the next pill at your regular time. This means you may take <content styleCode="bold">2</content> pills in <content styleCode="bold">1</content> day.</item>
                     <item>Then continue taking <content styleCode="bold">1</content> pill every day until you finish the pack.</item>
                     <item>You do not      need to use a back-up birth control method if you have sex.</item>
                  </list>
                  <paragraph ID="ID768">
                     <content styleCode="bold">If you miss 2 white pills in a row in Week 1 or Week 2 of your pack, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID769" styleCode="Disc">
                     <item>Take the 2 missed pills as soon      as possible and the next 2 pills the next day.</item>
                     <item>Then continue to take 1 pill      every day until you finish the pack.</item>
                     <item>Use a      non-hormonal birth control method (such as a condom and spermicide) as a      back-up if you have sex during the first 7 days after missing your pills.</item>
                  </list>
                  <paragraph ID="ID770">
                     <content styleCode="bold">If you miss 2 white pills in a row in Week 3 or Week 4, or you miss 3 or more white pills in a row at any time, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID771" styleCode="Disc">
                     <item>
                        <content styleCode="bold">If you are a Day 1 Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Throw out the rest of the pill pack and start a new pack that same day.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">If you are a Sunday Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Keep taking 1 pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of pills that same day.</item>
                        </list>
                     </item>
                     <item>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare provider because you might be pregnant.</item>
                     <item>You could become pregnant if you have sex during the first 7 days after you restart your pills. You MUST use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first 7 days after you restart your pills.</item>
                  </list>
                  <paragraph ID="ID772">
                     <content styleCode="bold">If you miss any of the 4 brown "reminder" pills in Week 4</content>, throw away the pills you missed and keep taking 1 pill each day until the pack is empty. You do not need to use a back-up method of birth control.</paragraph>
                  <paragraph>
                     <content styleCode="bold">If you have any questions or are unsure about the information in this leaflet, call your healthcare provider.</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
                  <paragraph ID="ID815">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) - 454 775</paragraph>
                  <paragraph>INDIA</paragraph>
                  <paragraph>This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: December 2024                                                                                ID#: 277045</paragraph>
               </text>
               <effectiveTime value="20241205"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>image-5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>image-6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID800">
               <id root="7849abb4-d7d6-43f3-ab25-4e1a0fafa7fd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID801">
                     <content styleCode="bold">Blisovi™ 24 Fe [norethindrone acetate and ethinyl estradiol tablets USP, (1 mg/0.02 mg) and ferrous fumarate tablets, (75 mg)]</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-864-71</paragraph>
                  <paragraph>Blister Label: 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
                  <paragraph ID="ID803">
                     <content styleCode="bold">Blisovi™ 24 Fe [norethindrone acetate and ethinyl estradiol tablets USP, (1 mg/0.02 mg) and ferrous fumarate tablets, (75 mg)]</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-864-71</paragraph>
                  <paragraph>Pouch Label: 1 blister of 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
                  <paragraph ID="ID805">
                     <content styleCode="bold">Blisovi™ 24 Fe [norethindrone acetate and ethinyl estradiol tablets USP, (1 mg/0.02 mg) and ferrous fumarate tablets, (75 mg)]</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-864-73</paragraph>
                  <paragraph>Carton Label: 3 blisters of 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
               </text>
               <effectiveTime value="20241205"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3055a6dd-97e3-42bd-be92-d1d67ee2e5fb-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>